Annotation Detail

Information
Associated Genes
CTLA4
Associated Variants
CTLA4 UNKNOWN
Source Database
MMMP
Description
In this phase II trial (metastatic setting), anti-CTLA4 antibody tremelimumab showed an objective response rate of 6.6%, with all responses being durable > or =170 days since enrollment
MMMP State
uncharacterized
MMMP Molecule
CTLA4
MMMP Relationship
no relationship with
MMMP Drug
Tremelimumab
MMMP Drug Alias
CTLA4 antibody (antagonist) CP-675,206
MMMP Model
5
MMMP Reference
Kirkwood JM, Clin Cancer Res 2010, 16:1042-8
Drugs
Drug NameSensitivitySupported
TremelimumabResitance or Non-Reponsetrue